Research & Development

Complementary Research & Development areas of expertise in immunology

Accelerating target identification, product validation and beyond

Delivering first-in-class therapies activating and regulating the immune system

Identification of new targets

OSE Immunotherapeutics integrated Research & Development engine focuses on developing innovative immunotherapies for immune regulation in the fields of Immuno-Oncology and Immuno-Inflammation. It is based on three areas of expertise in immunology:

Immuno-Oncology: focused on myeloid targets, Immuno-Inflammation, Preclinical platforms: Myeloid and BiCKI® platforms.

Building on unparalleled experience in clinical immunology initially applied to transplantion, OSE Immunotherapeutics research benefits from a fully translational platform fully intertwined with academic centers with complementary expertise in immunotherapy (INSERM, Center for Research in Transplantation and Immunology, University Hospital of Nantes, etc.).

Leveraging these collaborations and in-house expertise on novel target discovery, OSE Immunotherapeutics team identifies innovative agonists or antagonists of the immune response and generates viable therapeutics using the following technological platforms: optimized neo-epitopes, myeloid checkpoint inhibitors, monoclonal antibodies, and bispecific antibodies.


Complementary Research & Development areas of expertise in immunology


From target identification to product validation and beyond


First-in-class therapies activating and regulating the immune system


Tumor cells are usually recognized and destroyed through a complex mechanism of immune surveillance involving different immune cells (antigen presenting cells, macrophages, lymphocytes, etc.) and helper proteins (interleukins, growth factors, etc).

Tumor cells can escape this surveillance mechanism by blocking activation of immune cells. For example, they can express specific antigens that are also expressed by healthy cells to avoid being recognized, or block immune cell activation checkpoints to neutralize the immune response.

OSE Immunotherapeutics platform in immuno-oncology is focused on identification of specific targets to help the immune system recognize tumors and take appropriate action to kill them.

OSE Immunotherapeutics’ R&D team focuses on the key aspects of the immune response

Similar to cancer, autoimmune diseases are characterized by an abnormal immune reaction against normal cells

Ulcerative colitis, rheumatoid arthritis, Crohn’s disease, psoriasis and Sjögren’s syndrome are examples of the 80 different diseases that have been associated to autoimmune dysfunction.

Autoimmune dysfunction happens through a deregulation of the immune response or of immune cell maturation. As a result, immune cells target normal cells instead of disease cells, generating pathological situations that can profoundly affect the daily life of patients.

Alloreactivity (i.e. antigens from an individual of the same species but with a different genetic and tissue structure) remains a major obstacle to organ and tissue transplants since immunological rejections result in relatively rapid loss of the graft without immunosuppressive therapy. Alloreactive lymphocytes are at the heart of these rejections and develop high intensity immune responses that we try to block. OSE Immunotherapeutics develops monoclonal antibodies against innovative targets in order to regulate the response of myeloid cells (macrophages, neutrophils), T lymphocytes and antibodies with the common objective of restoring immune balance, restoring immune tolerance and / or triggering the resolution of inflammation.

Two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics

In parallel, OSE Immunotherapeutics expects to be able to generate further significant value from its two proprietary drug discovery platforms:

  • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform relying on the proprietary anti-PD1 backbone (OSE-279) to increase anti-tumor efficacy. The most advanced BiCKI® candidate is targeting anti-PD1xIL-7.
  • Myeloid platform, which is focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Preclinical programs from innovative research platforms

To receive OSE Immunotherapeutics’ latest news